A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Summary

This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with myocardial iron overload.

Timeline

Start

2017-11-30

Primary completion

2019-12-03

Completion

2020-01-14

Outcome

Outcome not reported

Stopped: “Terminated early for lack of efficacy as determined by interim endpoint analyses”

Drugs

Indications